Skip to content

    Jubilant Ingrevia Q4 FY26 earnings call

    JUBLINGREA
    Chemicals·26 May 2026
    Management Summary

    Jubilant Ingrevia reported a strong Q4 FY26, achieving its highest quarterly revenue and EBITDA in 14 quarters, driven by healthy double-digit growth in both top and bottom lines. The company saw robust performance in Specialty Chemicals and Nutrition, with effective management of Middle East disruptions and strategic acquisitions. While facing some challenges in acetic acid pricing and the slow agrochemical market, the company remains confident in sustained growth, particularly in Specialty Chemicals and Nutrition, supported by its Pinnacle Journey initiatives and CDMO pipeline.

    Highlights

    6

    • Highest quarterly revenue in 14 quarters at ₹1,179 crore, up 12% YoY.

    • EBITDA at ₹172 crore, up 11% YoY and 26% QoQ.

    • PAT at ₹86 crore, up 17% YoY and 84% QoQ.

    • Specialty Chemicals maintained 27% EBITDA margin for 6 quarters.

    • Net debt by EBITDA improved to 0.99x, with net debt reduced by 11% in 2026.

    • Successful dispatch of newly constructed agro CDMO facility and acquisition of Remidex Pharma to strengthen Human Nutrition.

    Concerns

    3

    • Potential for inventory impact in Q2 FY27 due to declining acetic acid prices.

    • Agrochemical industry moving slowly with massive cost pressures from China.

    • Volatility in Pyridine and Picoline pricing, though managed by the company.

    What Changed1

    vs Q1 FY27

    Guidance items7 → 5 (-2)
    Key financials

    Metrics

    5

    Periods

    2

    Headline

    4
    • Revenue
      ₹1,179 Cr
      YoY+12%
    • EBITDA
      ₹172 Cr
      YoY+11%QoQ+26%
    • PAT
      ₹86 Cr
      YoY+17%QoQ+84%
    • Net Debt to EBITDA
      0.99 x

    FY26

    1
    • EBITDA
      ₹510 Cr
      YoY+21%

    Segment breakdown

    • Specialty Chemicals₹516 Cr26.2%
    • Nutrition business₹230 Cr11.7%
    • Chemical Intermediates₹433 Cr22.0%
    • Nutrition business (FY26)₹790 Cr40.1%
    Donut· Share of Revenue

    Capital allocation

    4
    high confidence
    CategoryHeadline
    Capex

    ₹400 crores

    Debt

    1.0x EBITDA

    Dividend

    ₹2.5/share (final)

    M&A

    Remidex Pharma

    acquisition · closed

    Guidance & targets

    5
    CategoryTargetPriority
    Profitability
    EBITDA growth
    at least 20%
    		High
    Volume
    Agro CDMO growth
    accelerate growth
    		Medium
    Volume
    Human-grade B3 plant utilization (volumes)
    40-50% of peak level
    		Medium
    Capacity
    Pharma CDMO business size
    3x to 4x current size
    		Medium
    Margin
    Specialty Chemicals EBITDA Margin
    25% plus
    		High

    What to watch in Q1 FY27

    5

    Overall EBITDA growth

    FY27
    Current11% YoY (Q4 FY26), 21% YoY (FY26)
    TargetAt least 20% YoY

    Why it matters

    Key performance indicator for the company's 'Pinnacle Journey' and overall profitability.

    I think we have been pretty consistent in saying that if we take our EBITDA, we aspire to get at least 20% year-on-year growth in EBITDA on the full year basis.

    Risks & concerns

    4
    RiskSeverity

    Middle East supply chain disruptions and input cost increases

    Effectively handled Middle East crisis with no force majeure and 0 production loss, passing through higher crude-linked costs. — Management acknowledged

    medium

    Acetic acid price volatility and potential inventory losses

    Acetic acid prices are coming down; management is hopeful to nullify or minimize inventory impact in Q1/early Q2 FY27. — Analyst acknowledged

    medium

    Slowdown in agrochemical market and cost pressures from China

    Agrochemical industry is moving slowly with massive cost pressures from China, though the company is still gaining traction. — Management acknowledged

    medium

    Natural mortality rate for CDMO molecules in development phases

    Management mitigates this by maintaining a wide funnel of opportunities to ensure sufficient scale-up for pharma CDMO. — Management acknowledged

    low

    Q&A highlights

    8

    “When the war began in late February, we saw a sudden escalation in the raw material prices. But given our typical approach of having raw material inventory and locking in the raw material at the right price at the right time in an agile way, we started to see some benefits of that coming in last quarter itself as reflected in the acetyls business results for Q4 FY26. And we are hopeful that those benefits will continue in Q1 as well in a strong way.”

    Addresses the impact of raw material price volatility on the Chemical Intermediates segment and management's strategy to mitigate potential inventory losses.

    asked by Siddharth Gadekar

    2 min read5 chapters

    Detailed Narrative

    01

    Strong Q4 FY26 Performance Driven by Specialty Chemicals and Nutrition

    Jubilant Ingrevia reported its highest quarterly revenue in 14 quarters at ₹1,179 crore, marking a 12% year-on-year growth. EBITDA also saw a healthy increase of 11% year-on-year and 26% quarter-on-quarter to ₹172 crore, with PAT growing 17% year-on-year to ₹86 crore. This performance was primarily fueled by the Specialty Chemicals segment, which recorded ₹516 crore in revenue (up 6% YoY) and maintained a robust EBITDA margin of 27% for the sixth consecutive quarter. The Nutrition business also contributed significantly, with revenue up 21% year-on-year to ₹230 crore and EBITDA up 42% quarter-on-quarter to ₹32 crore.

    02

    Strategic Initiatives and Acquisitions Bolster Growth Outlook

    The company's 'Pinnacle Journey' initiatives, launched two years prior, are yielding visible results, including enhanced customer relationships and a robust opportunity pipeline with over 100 opportunities and ₹3,500 crore potential. Key highlights include the successful dispatch of a newly constructed agro CDMO facility and the acquisition of Remidex Pharma, aimed at strengthening the Human Nutrition premixes portfolio. These strategic moves are expected to accelerate growth, particularly in the CDMO and Human Nutrition segments, with the Gajraula MPP plant's construction progressing well for a Q4 FY27 production start.

    03

    Navigating Market Volatility and Cost Pressures

    Jubilant Ingrevia effectively managed Middle East disruptions, ensuring no force majeure🌐 and zero production loss, while passing through higher crude-linked costs to customers. Despite a resilient chemical industry demand, the agrochemical sector faces a slowdown and cost pressures from China. The company acknowledged potential inventory impacts from declining acetic acid prices in Q1/early Q2 FY27 but expressed confidence in minimizing negative effects through agile inventory management. Pyridine and Picoline markets continue to experience price volatility, though the company benefits from its global leadership and the 'China Plus One' trend.

    04

    Long-Term Growth Drivers and CDMO Pipeline Expansion

    The company's future growth is expected to be led by Specialty Chemicals and Nutrition, with a recovery in acetyls. The CDMO business, currently recognized within Specialty Chemicals, has been growing at 30-40% annually and is projected to accelerate further in FY27, with a target to grow the pharma CDMO business 3x to 4x its current size. The pipeline includes over 20 confirmed molecules and 10+ advanced stage molecules, with a significant portion (70%) of the pharma CDMO pipeline being non-Pyridine based, indicating diversified capabilities beyond its traditional strengths.

    05

    Capital Expenditure and Shareholder Returns

    For FY27, the company plans a capital expenditure of ₹400-500 crore, primarily for growth initiatives, including the Gajraula MPP plant. Net debt by EBITDA improved to 0.99x, with net debt reduced by 11% in 2026, reflecting a more efficient balance sheet. The Board recommended a final dividend of ₹2.5 per share, bringing the total FY26 dividend to ₹5 per share, resulting in a total cash outflow of ₹79.8 crore, demonstrating a commitment to shareholder returns.

    This is an AI-generated summary of a publicly available earnings call transcript.